Evidence map›Paper›PMID 35061735›Full record

ArticlePloS one2022

Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.

Antoine Bosquet, Comlan Affo, Ludovic Plaisance, Géraldine Poenou, Emmanuel Mortier, Isabelle Mahé

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Antoine BosquetAssistance-Publique-Hôpitaux de Paris (AP-HP), DMU ESPRIT, Service de Médecine Interne, Hôpital Louis-Mourier, Université de Paris, Colombes, France.ORCID 0000-0001-7282-6512
Comlan AffoAssistance-Publique-Hôpitaux de Paris (AP-HP), DMU ESPRIT, Service de Médecine Interne, Hôpital Louis-Mourier, Université de Paris, Colombes, France.
Ludovic PlaisanceUniversité de Paris, Assistance-Publique-Hôpitaux de Paris (AP-HP), DMU ESPRIT, Service de Médecine Interne, Hôpital Louis-Mourier, Colombes, France.
Géraldine PoenouUniversité de Paris, Assistance-Publique-Hôpitaux de Paris (AP-HP), DMU ESPRIT, Service de Médecine Interne, Hôpital Louis-Mourier, Colombes, France.
Emmanuel MortierAssistance-Publique-Hôpitaux de Paris (AP-HP), DMU ESPRIT, Policlinique, Hôpital Louis-Mourier, Colombes, France.
Isabelle MahéUniversité de Paris, Assistance-Publique-Hôpitaux de Paris (AP-HP), DMU ESPRIT, Service de Médecine Interne, Hôpital Louis-Mourier, Colombes, France.
Université Paris Cité · FRHôpital Louis-Mourier · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDuring the first wave of the coronavirus-disease 2019 (covid-19) pandemic in early 2020, hydroxychloroquine (HCQ) was widely prescribed in light of in vitro activity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Our objective was to evaluate in early 2020 the rate of French hospitalists declaring having prescribed HCQ to treat covid-19 patients outside any therapeutic trial, compare the reasons and the determinants for having prescribed HCQ or not. MATERIAL AND

methodsA national inquiry submitted by email from May 7 to 25, 2020, to a sample of French hospitalists: doctors managing patients hospitalized for covid-19 in a French department of internal medicine or infectious diseases and identified in the directories of French hospitals or as a member of the French Infectious Diseases Society (SPILF). Primary outcome was the percentage of hospitalists declaring having prescribed HCQ to covid-19 patients. Secondary outcomes were reasons and determinants of HCQ prescription.

resultsAmong 400 (22.8%) responding hospitalists, 45.3% (95% CI, 40.4 to 50.1%) declared having prescribed HCQ to covid-19 patients. Two main profiles were discerned: HCQ prescribers who did not raise its efficacy as a motive, and non-prescribers who based their decision on evidence-based medicine. Multivariate analysis retained the following prescription determinants (adjusted odds ratio; 95% confidence interval): a departmental procedure for HCQ prescription (8.25; 4.79 to 14.20), having prescribed other treatments outside a therapeutic trial (3.21; 1.81 to 5.71), prior HCQ prescription (2.75; 1.5 to 5.03) and HCQ prescribed within the framework of a therapeutic trial (0.56; 0.33 to 0.95).

conclusionAlmost half of the hospitalists prescribed HCQ. The physician's personality (questioning or not evidence-based-medicine principles in the context of the pandemic) and departmental therapeutic procedures were the main factors influencing HCQ prescription. Establishment of "therapeutic" procedures represents a potential means to improve the quality of therapeutic decision-making during a pandemic.

Indexed as

COVID-19 Drug TreatmentAntimalarialsAntiviral AgentsCOVID-19Drug RepositioningFranceHospitalistsHospitalizationHumansHydroxychloroquineOff-Label UsePractice Patterns, Physicians'PrescriptionsSARS-CoV-2Treatment OutcomeAntimalarialsAntiviral AgentsHydroxychloroquine

Identifiers

PMID35061735
PMCPMC8782345
OpenAlexW4206998008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.